Researchers have developed a distinctive bacterial barrier for administering cancer-fighting viruses
In a groundbreaking development, a new method for fighting tumors using oncolytic viruses delivered through specially modified bacteria has shown promising results. This approach, known as CAPPSID, leverages the natural ability of bacteria like Salmonella typhimurium to target and penetrate tumors, while shielding the oncolytic virus from the body's immune system[1][2][3].
Key Features
The bacteria act as a cloak, hiding the virus from circulating antibodies and ferrying it into the tumor environment[1][3]. This "bacterial cloaking" ensures the virus reaches its target, bypassing the main barrier to therapy: the rapid destruction of viruses by antibodies and their poor penetration into tumor tissues.
The bacteria home in on the hypoxic and nutrient-rich environment within tumors, ensuring the virus reaches its target[1][3]. This targeted delivery mechanism enhances the therapeutic efficacy of the treatment.
Once inside tumor cells, the virus, such as Senecavirus A (SVA), replicates and kills cancer cells[3]. The system includes safeguards to prevent the virus from spreading outside the tumor by ensuring that viral particles can only mature in the presence of bacterial machinery[2].
Effectiveness
The bacterial cloak helps the virus evade prior immunity in patients, overcoming a major limitation of traditional viral therapies[1][3]. This evasion of immune response, combined with the bacteria's facilitation of deep penetration and spread of the virus within tumors, enhances the overall effectiveness of the treatment.
Research is ongoing to translate this technology into clinical applications, with hopes to develop a "toolkit" of viral therapies for various cancer types[2].
Future Directions
While this method shows promise, further research is needed to optimize its safety and efficacy in human trials. The team is exploring the use of different tumor models and viruses to expand its applicability[2].
In mouse experiments, this method resulted in higher viral accumulation in tumors[4]. The bacteria used in this method is an attenuated strain of Salmonella typhimurium, which accumulates in hypoxic areas of the tumor[5]. The bacteria act as a "Trojan horse," delivering the Senecavirus A virus to cancer cells[6]. Once in the tumor, the virus begins to replicate and destroy cells, causing a chain reaction of infection.
This approach offers a novel strategy for delivering oncolytic viruses directly into tumors, potentially improving outcomes for patients with solid tumors. The information about the effectiveness of this method is based on findings from pronedra.ru.
References: 1. Article 1 2. Article 2 3. Article 3 4. Article 4 5. Article 5 6. Article 6
Science and health-and-wellness sectors are buzzing about the groundbreaking development of a new method for cancer treatment, dubbed CAPPSID. This innovative approach involves the use of oncolytic viruses, such as Senecavirus A (SVA), delivered through specially modified bacteria like Salmonella typhimurium. By leveraging the bacteria's ability to target and penetrate tumors while shielding the virus from the immune system, this method shows promise in addressing medical-conditions like cancer.
